Mechanisms Contributing to Acquired Activated Protein C Resistance in
Patients Treated with Thalidomide: A Molecular Dynamics Study

Correa   Lara   Maximiliano; García   Chavez   Jaime; Vega   Lopez   Armando; Israel   Lara   Vega; Hernandez   Gonzalez   Victoria; Martinez   Hernandez   Erika

doi:10.2174/1871529X23666230123121602

Abstract

Introduction: There is a high incidence of venous thromboembolism (VTE) in patients with Multiple Myeloma (MM), however; until now, the exact mechanisms behind VTE in MM are unknown, and some of the elements that may play a significant role are the treatment with an immunomodulator (IMiD) and acquired resistance to activated protein C (APC).

Objective: The study aims to reveal the possible mechanisms linked to the reduced antithrombotic activity of APC associated with thalidomide.

Methods: The molecular docking approach was used to ascertain the in silico inhibitory potential of thalidomide on the APC protease domain in the architecture of the catalytic triad and its interaction with major substrate binding sites.

Results: The coupling showed that the inhibitory activity of thalidomide depends on the induction of structural changes in the protease domain of APC, at the level of the Ser/His/Asp catalytic triad, as a result of a significant increase between the distances of CαAsp102 and Cα Ser195 (11.175 angstroms, increase 14.83%) and between CαSer195 and CαHis57 (9.478 angstroms, increase 13.78 %). This can result in an inefficient transfer of the proton between these residues, the other possible mechanism of inhibition, is a potential reduced binding of the substrate as a result of a direct interaction through a carbon-hydrogen bond on His57, an H-bond on Arg306, and a carbon hydrogen bond on Arg506.

Conclusion: We demonstrate the in silico inhibitory potential of thalidomide on APC, through two possible inhibition mechanisms, a pathophysiologically relevant finding to understand the factors that can affect the stability and functions of APC in vivo.

« Previous Next »

Graphical Abstract

[1]
Timp, J.F.; Braekkan, S.K.; Versteeg, H.H.; Cannegieter, S.C. Epidemiology of cancer-associated venous thrombosis. Blood,  2013, 122(10), 1712-1723.
 [http://dx.doi.org/10.1182/blood-2013-04-460121] [PMID:  23908465]

[2]
Pabinger, I.; Thaler, J.; Ay, C. Biomarkers for prediction of venous thromboembolism in cancer. Blood,  2013, 122(12), 2011-2018.
 [http://dx.doi.org/10.1182/blood-2013-04-460147] [PMID:  23908470]

[3]
Barsam, S.J.; Patel, R.; Arya, R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. Br. J. Haematol.,  2013, 161(6), 764-777.
 [http://dx.doi.org/10.1111/bjh.12314] [PMID:  23560605]

[4]
Falanga, A.; Marchetti, M.; Vignoli, A. Coagulation and cancer: biological and clinical aspects. J. Thromb. Haemost.,  2013, 11(2), 223-233.
 [http://dx.doi.org/10.1111/jth.12075] [PMID:  23279708]

[5]
Falanga, A.; Iacoviello, L.; Evangelista, V.; Belotti, D.; Consonni, R.; D’Orazio, A.; Robba, L.; Donati, M.B.; Barbui, T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered alltrans-retinoic acid. Blood,  1995, 86(3), 1072-1081.
 [http://dx.doi.org/10.1182/blood.V86.3.1072.1072] [PMID:  7620161]

[6]
Kwaan, H.; Keer, H. Fibrinolysis and cancer. Semin. Thromb. Hemost.,  1990, 16(3), 230-235.
 [http://dx.doi.org/10.1055/s-2007-1002674] [PMID:  2146746]

[7]
Grignani, G.; Maiolo, A. Cytokines and hemostasis. Haematologica,  2000, 85(9), 967-972.
 [PMID:  10980636]

[8]
Blom, J.W.; Doggen, C.J.; Osanto, S.; Rosendaal, F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA,  2005, 293(6), 715-722.
 [http://dx.doi.org/10.1001/jama.293.6.715] [PMID:  15701913]

[9]
Chew, H.K.; Wun, T.; Harvey, D.; Zhou, H.; White, R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med.,  2006, 166(4), 458-464.
 [http://dx.doi.org/10.1001/archinte.166.4.458] [PMID:  16505267]

[10]
Alcalay, A.; Wun, T.; Khatri, V.; Chew, H.K.; Harvey, D.; Zhou, H.; White, R.H. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J. Clin. Oncol.,  2006, 24(7), 1112-1118.
 [http://dx.doi.org/10.1200/JCO.2005.04.2150] [PMID:  16505431]

[11]
Cronin-Fenton, D.P.; Søndergaard, F.; Pedersen, L.A.; Fryzek, J.P.; Cetin, K.; Acquavella, J.; Baron, J.A.; Sørensen, H.T. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br. J. Cancer,  2010, 103(7), 947-953.
 [http://dx.doi.org/10.1038/sj.bjc.6605883] [PMID:  20842120]

[12]
Anderson, L.A.; Moore, S.C.; Gridley, G.; Stone, B.J.; Landgren, O. Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk. Lymphoma,  2011, 52(5), 764-770.
 [http://dx.doi.org/10.3109/10428194.2010.551572] [PMID:  21271864]

[13]
De Martino, R.R.; Goodney, P.P.; Spangler, E.L.; Wallaert, J.B.; Corriere, M.A.; Rzucidlo, E.M.; Walsh, D.B.; Stone, D.H. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J. Vasc. Surg.,  2012, 55(4), 1035-1040.e4.
 [http://dx.doi.org/10.1016/j.jvs.2011.10.129] [PMID:  22409858]

[14]
Hultcrantz, M.; Björkholm, M.; Dickman, P.W.; Landgren, O.; Derolf, Å.R.; Kristinsson, S.Y.; Andersson, T.M.L. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms. Ann. Intern. Med.,  2018, 168(5), 317-325.
 [http://dx.doi.org/10.7326/M17-0028] [PMID:  29335713]

[15]
Srkalovic, G.; Cameron, M.G.; Rybicki, L.; Deitcher, S.R. Kattke- Marchant, K.; Hussein, MA. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer,  2004, 101, 558-566.
 [http://dx.doi.org/10.1002/cncr.20405] [PMID:  15274069]

[16]
Rajkumar, S.V.; Blood, E.; Vesole, D.; Fonseca, R.; Greipp, P.R. Eastern Cooperative Oncology Group Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.,  2006, 24(3), 431-436.
 [http://dx.doi.org/10.1200/JCO.2005.03.0221] [PMID:  16365178]

[17]
Zangari, M.; Saghafifar, F.; Mehta, P.; Barlogie, B.; Fink, L.; Tricot, G. The blood coagulation mechanism in multiple myeloma. Semin. Thromb. Hemost.,  2003, 29(3), 275-282.
 [http://dx.doi.org/10.1055/s-2003-40965] [PMID:  12888931]

[18]
Rajkumar, S.V.; Gertz, M.A.; Lacy, M.Q.; Dispenzieri, A.; Fonseca, R.; Geyer, S.M.; Iturria, N.; Kumar, S.; Lust, J.A.; Kyle, R.A.; Greipp, P.R.; Witzig, T.E. Thalidomide as initial therapy for early-stage myeloma. Leukemia,  2003, 17(4), 775-779.
 [http://dx.doi.org/10.1038/sj.leu.2402866] [PMID:  12682636]

[19]
Weber, D.; Rankin, K.; Gavino, M.; Delasalle, K.; Alexanian, R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol.,  2003, 21(1), 16-19.
 [http://dx.doi.org/10.1200/JCO.2003.03.139] [PMID:  12506164]

[20]
Cavo, M.; Zamagni, E.; Tosi, P.; Cellini, C.; Cangini, D.; Tacchetti, P.; Testoni, N.; Tonelli, M.; de Vivo, A.; Palareti, G.; Tura, S.; Baccarani, M. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica,  2004, 89(7), 826-831.
 [PMID:  15257934]

[21]
Rajkumar, S.V.; Hayman, S.; Gertz, M.A.; Dispenzieri, A.; Lacy, M.Q.; Greipp, P.R.; Geyer, S.; Iturria, N.; Fonseca, R.; Lust, J.A.; Kyle, R.A.; Witzig, T.E. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol.,  2002, 20(21), 4319-4323.
 [http://dx.doi.org/10.1200/JCO.2002.02.116] [PMID:  12409330]

[22]
Palumbo, A.; Bringhen, S.; Caravita, T.; Merla, E.; Capparella, V.; Callea, V.; Cangialosi, C.; Grasso, M.; Rossini, F.; Galli, M.; Catalano, L.; Zamagni, E.; Petrucci, M.T.; De Stefano, V.; Ceccarelli, M.; Ambrosini, M.T.; Avonto, I.; Falco, P.; Ciccone, G.; Liberati, A.M.; Musto, P.; Boccadoro, M. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet,  2006, 367(9513), 825-831.
 [http://dx.doi.org/10.1016/S0140-6736(06)68338-4] [PMID:  16530576]

[23]
Facon, T.; Mary, J.Y.; Hulin, C.; Benboubker, L.; Attal, M.; Pegourie, B.; Renaud, M.; Harousseau, J.L.; Guillerm, G.; Chaleteix, C.; Dib, M.; Voillat, L.; Maisonneuve, H.; Troncy, J.; Dorvaux, V.; Monconduit, M.; Martin, C.; Casassus, P.; Jaubert, J.; Jardel, H.; Doyen, C.; Kolb, B.; Anglaret, B.; Grosbois, B.; Yakoub-Agha, I.; Mathiot, C.; Avet-Loiseau, H. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet,  2007, 370(9594), 1209-1218.
 [http://dx.doi.org/10.1016/S0140-6736(07)61537-2] [PMID:  17920916]

[24]
Dimopoulos, M.A.; Anagnostopoulos, A.; Terpos, E.; Repoussis, P.; Zomas, A.; Katodritou, E.; Kyrtsonis, M.C.; Delibasi, S.; Vassou, A.; Pouli, A.; Zervas, K.; Anagnostopoulos, N.; Maniatis, A. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica,  2006, 91(2), 252-254.
 [PMID:  16461313]

[25]
Osman, K.; Comenzo, R.; Rajkumar, S.V. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N. Engl. J. Med.,  2001, 344(25), 1951-1952.
 [http://dx.doi.org/10.1056/NEJM200106213442516] [PMID:  11419443]

[26]
Schütt, P.; Ebeling, P.; Buttkereit, U.; Brandhorst, D.; Opalka, B.; Hoiczyk, M.; Flasshove, M.; Hense, J.; Bojko, P.; Metz, K.; Moritz, T.; Seeber, S.; Nowrousian, M.R. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur. J. Haematol.,  2005, 74(1), 40-46.
 [http://dx.doi.org/10.1111/j.1600-0609.2004.00349.x] [PMID:  15613105]

[27]
Zervas, K.; Dimopoulos, M.A.; Hatzicharissi, E.; Anagnostopoulos, A.; Papaioannou, M.; Mitsouli, C.; Panagiotidis, P.; Korantzis, J.; Tzilianos, M.; Maniatis, A. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone(T-VAD doxil): a phase II multicenter study. Ann. Oncol.,  2004, 15(1), 134-138.
 [http://dx.doi.org/10.1093/annonc/mdh026] [PMID:  14679133]

[28]
Sidra, G.; Williams, C.D.; Russell, N.H.; Zaman, S.; Myers, B.; Byrne, J.L. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica,  2006, 91(6), 862-863.
 [PMID:  16769594]

[29]
Wu, P.; Davies, F.E.; Horton, C.; Jenner, M.W.; Krishnan, B.; Alvares, C.L.; Saso, R.; Mccormack, R.; Dines, S.; Treleaven, J.G.; Potter, M.N.; Ethell, M.E.; Morgan, G.J. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk. Lymphoma,  2006, 47(11), 2335-2338.
 [http://dx.doi.org/10.1080/10428190600821955] [PMID:  17107906]

[30]
Barlogie, B.; Tricot, G.; Anaissie, E.; Shaughnessy, J.; Rasmussen, E.; van Rhee, F.; Fassas, A.; Zangari, M.; Hollmig, K.; Pineda-Roman, M.; Lee, C.; Talamo, G.; Thertulien, R.; Kiwan, E.; Krishna, S.; Fox, M.; Crowley, J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med.,  2006, 354(10), 1021-1030.
 [http://dx.doi.org/10.1056/NEJMoa053583] [PMID:  16525139]

[31]
Zangari, M.; Siegel, E.; Barlogie, B.; Anaissie, E.; Saghafifar, F.; Fassas, A.; Morris, C.; Fink, L.; Tricot, G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood,  2002, 100(4), 1168-1171.
 [http://dx.doi.org/10.1182/blood-2002-01-0335] [PMID:  12149193]

[32]
Gonzalez, K. Altered levels of coagulation factors in patients with multiple myeloma treated with thalidomide; , 2010.  Available from:  https://132.248.9.195/ptb2010/mayo/0658255/Index.html

[33]
Corso, A.; Lorenzi, A.; Terulla, V.; Airò, F.; Varettoni, M.; Mangiacavalli, S.; Zappasodi, P.; Rusconi, C.; Lazzarino, M. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann. Hematol.,  2004, 83(9), 588-591.
 [http://dx.doi.org/10.1007/s00277-004-0891-6] [PMID:  15235749]

[34]
Kaushal, V.; Kaushal, G.P.; Melkaveri, S.N.; Mehta, P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J. Thromb. Haemost.,  2004, 2(2), 327-334.
 [http://dx.doi.org/10.1046/j.1538-7933.2003.00573.x] [PMID:  14995997]

[35]
Minnema, M.C.; Fijnheer, R.; De Groot, P.G.; Lokhorst, H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J. Thromb. Haemost.,  2003, 1(3), 445-449.
 [http://dx.doi.org/10.1046/j.1538-7836.2003.00083.x] [PMID:  12871448]

[36]
Pal, R.; Monaghan, S.A.; Hassett, A.C.; Mapara, M.Y.; Schafer, P.; Roodman, G.D.; Ragni, M.V.; Moscinski, L.; List, A.; Lentzsch, S. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood,  2010, 115(3), 605-614.
 [http://dx.doi.org/10.1182/blood-2009-05-221077] [PMID:  19965623]

[37]
Zangari, M.; Saghafifar, F.; Anaissie, E.; Badros, A.; Desikan, R.; Fassas, A.; Mehta, P.; Morris, C.; Toor, A.; Whitfield, D.; Siegel, E.; Barlogie, B.; Fink, L.; Tricot, G. Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul. Fibrinolysis,  2002, 13(3), 187-192.
 [http://dx.doi.org/10.1097/00001721-200204000-00003] [PMID:  11943931]

[38]
Elice, F.; Fink, L.; Tricot, G.; Barlogie, B.; Zangari, M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br. J. Haematol.,  2006, 134(4), 399-405.
 [http://dx.doi.org/10.1111/j.1365-2141.2006.06208.x] [PMID:  16882132]

[39]
Dahlbäck, B.; Villoutreix, B.O. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler. Thromb. Vasc. Biol.,  2005, 25(7), 1311-1320.
 [http://dx.doi.org/10.1161/01.ATV.0000168421.13467.82] [PMID:  15860736]

[40]
Mosnier, L.O.; Griffin, J.H. Protein C, protein S, thrombomodulin and the endothelial protein C receptor pathways. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice; Marder, V.J.; Aird, W.C.; Bennett, J.S.; Schulman, S.; White, G.C.; Colman, R.W., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2013; pp. 300-313.

[41]
a) Mather, T.; Oganessyan, V.; Hof, P.; Huber, R.; Foundling, S.; Esmon, C.T. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J.,  1996, 15, 6822-6831.; 
b) Esmon, C.T.; Owen, W.G. Identification of an endothelial cell cofactor for thrombin cata- lyzed activation of protein C. Proc. Natl. Acad. Sci. USA,  1981, 78, 2249-2252.

[42]
Mann, K.G.; Kalafatis, M.; Factor, V. A combination of Dr Jekyll and Mr Hyde. Blood,  2003, 101(1), 20-30.
 [http://dx.doi.org/10.1182/blood-2002-01-0290] [PMID:  12393635]

[43]
Nicolaes, G.A.F.; Dahlbäck, B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler. Thromb. Vasc. Biol.,  2002, 22(4), 530-538.
 [http://dx.doi.org/10.1161/01.ATV.0000012665.51263.B7] [PMID:  11950687]

[44]
Lenting, P.J.; van Mourik, J.A.; Mertens, K. The life cycle of coagulation factor VIII in view of its structure and function. Blood,  1998, 92(11), 3983-3996.
 [http://dx.doi.org/10.1182/blood.V92.11.3983] [PMID:  9834200]

[45]
Váradi, K.; Rosing, J.; Tans, G.; Pabinger, I.; Keil, B.; Schwarz, H.P. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb. Haemost.,  1996, 76(2), 208-214.
 [http://dx.doi.org/10.1055/s-0038-1650556] [PMID:  8865533]

[46]
Fay, P. Regulation of factor VIIIa in the intrinsic factor Xase. Thromb. Haemost.,  1999, 82(8), 193-200.
 [http://dx.doi.org/10.1055/s-0037-1615833] [PMID:  10605704]

[47]
O’Boyle, N.M.; Banck, M.; James, C.A.; Morley, C.; Vandermeersch, T.; Hutchison, G.R. Open Babel: An open chemical toolbox. J. Cheminform.,  2011, 3(1), 33.
 [http://dx.doi.org/10.1186/1758-2946-3-33] [PMID:  21999342]

[48]
Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem.,  2009, 30(16), 2785-2791.
 [http://dx.doi.org/10.1002/jcc.21256] [PMID:  19399780]

[49]
Iheagwam, F.N.; Ogunlana, O.O.; Chinedu, S.N. Model optimization and in silico analysis of potential dipeptidyl peptidase IV antagonists from GC-MS identified compounds in Nauclea latifolia leaf extracts. Int. J. Mol. Sci.,  2019, 20(23), 5913.
 [http://dx.doi.org/10.3390/ijms20235913] [PMID:  31775302]

[50]
Forli, S.; Huey, R.; Pique, M.E.; Sanner, M.F.; Goodsell, D.S.; Olson, A.J. Computational protein–ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc.,  2016, 11(5), 905-919.
 [http://dx.doi.org/10.1038/nprot.2016.051] [PMID:  27077332]

[51]
Tarcsay, Á.; Nyíri, K. Keserű G.M. Impact of lipophilic efficiency on compound quality. J. Med. Chem.,  2012, 55(3), 1252-1260.
 [http://dx.doi.org/10.1021/jm201388p] [PMID:  22229549]

[52]
Yang, J.F.; Wang, F.; Chen, Y.Z.; Hao, G.F.; Yang, G.F. LARMD: integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor. Brief. Bioinform.,  2020, 21(6), 2206-2218.
 [http://dx.doi.org/10.1093/bib/bbz141] [PMID:  31799600]

[53]
Nalian, A.; Iakhiaev, A.V. Possible mechanisms contributing to oxidative inactivation of activated protein C: Molecular dynamics study. Thromb. Haemost.,  2008, 100(7), 18-25.
 [http://dx.doi.org/10.1160/TH07-12-0750] [PMID:  18612533]

[54]
Bertina, R.M.; Koeleman, B.P.C.; Koster, T.; Rosendaal, F.R.; Dirven, R.J.; de Ronde, H.; van der Velden, P.A.; Reitsma, P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature,  1994, 369(6475), 64-67.
 [http://dx.doi.org/10.1038/369064a0] [PMID:  8164741]

[55]
Williamson, D.; Brown, K.; Luddington, R.; Baglin, C.; Baglin, T.; Factor, V.; Factor, V. Cambridge: a new mutation (Arg306-->Thr) associated with resistance to activated protein C. Blood,  1998, 91(4), 1140-1144.
 [http://dx.doi.org/10.1182/blood.V91.4.1140] [PMID:  9454742]

[56]
Chan, W.P.; Lee, C.K.; Kwong, Y.L.; Lam, C.K.; Liang, R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood,  1998, 91(4), 1135-1139.
 [http://dx.doi.org/10.1182/blood.V91.4.1135] [PMID:  9454741]

[57]
Steen, M.; Norstrøm, E.A.; Tholander, A.L.; Bolton-Maggs, P.H.; Mumford, A.; McVey, J.H.; Tuddenham, E.G.; Dahlbäck, B. Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood,  2004, 103(9), 3381-3387.
 [http://dx.doi.org/10.1182/blood-2003-06-2092] [PMID:  14695241]

[58]
Roelse, J.C.; Koopman, M.M.W.; Büller, H.R.; Ten Cate, J.W.; Montaruli, B.; Van Mourik, J.A.; Voorberg, J. Absence of mutations at the activated protein C cleavage sites of factor VIII in 125 patients with venous thrombosis. Br. J. Haematol.,  1996, 92(3), 740-743.
 [http://dx.doi.org/10.1046/j.1365-2141.1996.349885.x] [PMID:  8616046]

[59]
Bokarewa, M.I.; Falk, G.; Bremme, K.; Blombäck, M.; Wiman, B. Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance. Eur. J. Clin. Invest.,  1997, 27(4), 340-345.
 [http://dx.doi.org/10.1046/j.1365-2362.1997.1180660.x] [PMID:  9134384]

[60]
Groth, J.; Flayeh, R.; Wagener, C.; Jung, R.; Brümmer, J. Absence of mutations at the APC interacting sites of factor VIII in Caucasians. Thromb. Haemost.,  2002, 87(1), 170.
 [http://dx.doi.org/10.1055/s-0037-1612962] [PMID:  11848448]

[61]
Iengar, P.; Ramakrishnan, C. Knowledge-based modeling of the serine protease triad into non-proteases. Protein Eng. Des. Sel.,  1999, 12(8), 649-656.
 [http://dx.doi.org/10.1093/protein/12.8.649] [PMID:  10469825]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1871529X23666230123121602	Print ISSN 1871-529X
Publisher Name Bentham Science Publisher	Online ISSN 2212-4063

Cardiovascular & Hematological Disorders-Drug Targets

Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract